1. Scrip
  2. >>Business
  3. >>Earnings

Infographic: Scrip 100 Numbers Crunched

 
• By John Hodgson

This year's Scrip 100 collection is bigger than ever, encompassing 2016 full-year financial data from more than 650 biopharmaceutical companies.

Numbers Crunched

The full set of businesses analyzed in our Scrip 100 annual review saw a total profit of $136.8bn in 2016 – and the top 20 pharmas in the sector were responsible for 87% of the industry's gains. Below, we crunch the numbers and provide a quick take on how the biopharma sector performed in 2016.

This year's Scrip 100 edition, which will go live on Dec. 21, includes exclusive features across a broad range of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Japan H1 Roundup: Pipeline Shifts Bring Mixed Results

 
• By Lisa Takagi

While Astellas and Daiichi Sankyo rang in double-digit growth, Eisai offset LOE impact with Leqembi’s performance. Takeda struggled with negative results but announced several growth initiatives.

Bayer Boss Cautious On Late-Stage Deals Despite Beyonttra Success

 
• By Kevin Grogan

CEO Bill Anderson tells Scrip that the German group looks at potential in-licensing opportunities across every stage of the pipeline “but as you know, good value is a lot harder to come by in the late stage.”

Stock Watch: CEO’s Bullish Projection Helps GSK Outshine Merck

 
• By Andy Smith

Reduced immunization rates in the US marred the results of both GSK and Merck, but with Merck’s biggest drug approaching its loss of exclusivity, lower vaccine sales and sluggish new product revenues spooked investors. GSK left more room for optimism.

Aye Or Nay To Biosimilars For Sun Amid US Regulatory Easing?

 
• By Anju Ghangurde

Sun’s specialty gambit reaps gains with US sales surpassing generics for the first time in Q2 FY26, but will it finally enter the fray for biosimilars as the US moves to simplify regulatory requirements in the segment?

More from Business

Investors Shower Chinese In Vivo CAR-T Biotechs With Quick Cash

 
• By Dexter Jie Yan

Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.

MASH Updates: Sagimet, Altimmune, GSK Discuss Development Plans At AASLD

 
• By Joseph Haas

Sagimet may shift focus to later-stage MASH while it lines up Phase III financing. Altimmune expects its dual agonist to show efficacy and tolerability, while GSK is readying efimosfermin as the third FGF21 analog into Phase III for MASH.

Finance Watch: Public Biopharma Company Financings Surged Globally In Q3

 
• By Mandy Jackson

Public Company Financings: Biomedtracker’s third quarter report shows a big jump from Q2 in follow-on offerings, private placements and debt. Also, Evommune brings the US biopharma IPO tally for 2025 to a dozen and Merck’s Blackstone deal gives it $700m to develop a key ADC asset.